Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy

Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy

Background: Our study measured the body composition of Diffuse large B-cell lymphoma (DLBCL) patients receiving rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimen by computed tomographic (CT) and assessed their correlation with treatment-related toxicity and ot...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Jiaxun Guo, Panpan Cai, Pengfei Li, Cong Cao, Jing Zhou, Lina Dong, Yan Yang, Qijia Xuan, Jingxuan Wang, Qingyuan Zhang
Fformat:	Erthygl
Iaith:	English
Cyhoeddwyd:	MDPI AG 2021-03-01
Cyfres:	Current Oncology
Pynciau:	diffuse large B-cell lymphoma immunochemotherapy survival sarcopenia toxicity
Mynediad Ar-lein:	https://www.mdpi.com/1718-7729/28/2/126

Eitemau Tebyg

Primary hepatic diffuse large B-cell lymphoma with favorable response to immunochemotherapy
gan: Nai-Wen Kang, et al.
Cyhoeddwyd: (2017-12-01)

Radiotherapy after immunochemotherapy improves outcomes in patients with primary mediastinal large B‐cell lymphoma
gan: Agustin Avilés, et al.
Cyhoeddwyd: (2019-12-01)

An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
gan: Marta Rodríguez, et al.
Cyhoeddwyd: (2022-08-01)

The role of the gut microbiota in infectious complications during immunochemotherapy for diffuse large B-cell lymphoma
gan: Man Sun, et al.
Cyhoeddwyd: (2024-12-01)

Personalized genotype-directed antitumor therapy for newly diagnosed diffuse large B-cell lymphoma: efficacy and toxicity of the R-CHOP-X protocol in a single-center, non-randomized, prospective clinical trial (first results)
gan: M. A. Mingalimov, et al.
Cyhoeddwyd: (2024-12-01)

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
gan: Laurie H. Sehn, et al.
Cyhoeddwyd: (2020-06-01)

Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
gan: Francisco‐Javier Peñalver, et al.
Cyhoeddwyd: (2019-11-01)

Efficacy of front‐line immunochemotherapy for transplant‐ineligible mantle cell lymphoma: A network meta‐analysis of randomized controlled trials
gan: Caixia Jing, et al.
Cyhoeddwyd: (2023-07-01)

Primary Bone Lymphoma of the Scapula
gan: Josip Lovaković, et al.
Cyhoeddwyd: (2024-02-01)

Objectification of the method for glomerular filtration rate assessing in patients with diffuse large B-cell lymphoma during induction immunochemotherapy
gan: A. S. Nozdricheva, et al.
Cyhoeddwyd: (2024-04-01)

An Economic Evaluation of the TROG 99.03 Trial: Systemic Therapy After Radiotherapy in Early‐Stage Follicular Lymphoma
gan: Daniel Erku, et al.
Cyhoeddwyd: (2025-02-01)

Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma – a Single-center, Retrospective Study
gan: David Belada, et al.
Cyhoeddwyd: (2007-01-01)

Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment
gan: VPCP Toledo, et al.
Cyhoeddwyd: (2001-01-01)

Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
gan: Ganesh Yadagiri, et al.
Cyhoeddwyd: (2023-05-01)

The long‐term risk of immune‐related conditions in survivors of diffuse large B‐cell lymphoma: A Danish nationwide registry study
gan: Laura Schou Pedersen, et al.
Cyhoeddwyd: (2025-02-01)

Biweekly CHOP therapy improves therapeutic effect in the non-GCB subtype of diffuse large B-cell lymphoma
gan: Zhang Qingyuan, et al.
Cyhoeddwyd: (2007-12-01)

Are more courses of immunochemotherapy beneficial for the short‐term outcome of locally advanced esophageal squamous cell carcinoma?
gan: Yuanheng Huang, et al.
Cyhoeddwyd: (2023-05-01)

Neoadjuvant immunochemotherapy for pulmonary large-cell neuroendocrine carcinoma: case report
gan: Chang Xu, et al.
Cyhoeddwyd: (2024-04-01)

Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients
gan: Gisele R. Gouveia, et al.
Cyhoeddwyd: (2020-10-01)

Neoadjuvant immunochemotherapy—a promising strategy for primary pulmonary lymphoepithelioma-like carcinoma
gan: Jiawei Chen, et al.
Cyhoeddwyd: (2024-12-01)

Immunotherapy and immunochemotherapy in visceral leishmaniasis: promising treatments for this neglected disease
gan: Bruno Mendes Roatt, et al.
Cyhoeddwyd: (2014-06-01)

More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features
gan: Lucijanic M, et al.
Cyhoeddwyd: (2021-09-01)

Prediction of 5‐year overall survival of diffuse large B‐cell lymphoma on the pola‐R‐CHP regimen based on 2‐year event‐free survival and progression‐free survival
gan: Wan‐Ru Zhang, et al.
Cyhoeddwyd: (2024-01-01)

Association of the Scottish inflammatory prognostic score with treatment-related adverse events and prognosis in esophageal cancer receiving neoadjuvant immunochemotherapy
gan: Qiang Zhao, et al.
Cyhoeddwyd: (2024-07-01)

Appropriate Treatment Intensity for Diffuse Large B-Cell Lymphoma in the Older Population: A Review of the Literature
gan: Satoshi Yamasaki
Cyhoeddwyd: (2024-05-01)

Clinical efficacy of prophylactic intravenous immunoglobulin for elderly DLBCL patients with hypogammaglobulinemia in the COVID-19 pandemic era
gan: Dong Won Baek, et al.
Cyhoeddwyd: (2024-04-01)

Long‐term survival outcomes of patients with primary ocular adnexal MALT lymphoma: A large single‐center cohort study
gan: Yuanzheng Liang, et al.
Cyhoeddwyd: (2023-02-01)

Intravascular large B-cell lymphoma as a covert trigger for hemophagocytic lymphohistiocytosis complicated with capillary leak syndrome: a case report and literature review
gan: Jingjing Wen, et al.
Cyhoeddwyd: (2024-07-01)

A rare case of primary follicular lymphoma of the spleen
gan: Yerraguntla Subrahmanya Sarma, et al.
Cyhoeddwyd: (2016-01-01)

Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)
gan: Yingyi Li, et al.
Cyhoeddwyd: (2025-02-01)

Two rare cases of bronchus‐associated lymphoid tissue lymphoma successfully treated with rituximab‐bendamustine
gan: Nydia Panitz, et al.
Cyhoeddwyd: (2021-08-01)

Pediatric follicular lymphoma: literature review and presentation of a rare clinical case
gan: A. S. Volkova, et al.
Cyhoeddwyd: (2024-09-01)

Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphOCYtic leukemia
gan: Tamara Pavlovna Zagoskina, et al.
Cyhoeddwyd: (2010-03-01)

Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas
gan: Shenon Sethi, et al.
Cyhoeddwyd: (2021-11-01)

Single‐cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma
gan: Yaofei Jiang, et al.
Cyhoeddwyd: (2024-10-01)

Inorganic Nanozyme with Combined Self-Oxygenation/Degradable Capabilities for Sensitized Cancer Immunochemotherapy
gan: Jie Wang, et al.
Cyhoeddwyd: (2019-09-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
gan: T. D. Lutskaya, et al.
Cyhoeddwyd: (2014-07-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
gan: T. D. Lutskaya, et al.
Cyhoeddwyd: (2014-07-01)

Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
gan: Soyeon Choi, et al.
Cyhoeddwyd: (2022-09-01)

Prediction of pathological response to neoadjuvant immunochemotherapy with baseline and post-treatment 18F-FDG PET imaging biomarkers in patients with locally advanced gastric cancer
gan: Mimi Xu, et al.
Cyhoeddwyd: (2025-02-01)